SCHEMBL4379562

SCHEMBL4379562

C=CCC(=O)N1CCC(=NOCc2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TEAD1 P28347 3/20 0.42
LMNA P02545 3/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
NR4A2 P43354 2/20 0.39
PRKCA P17252 1/20 0.39
PRKCD Q05655 1/20 0.39
CNR1 P21554 1/20 0.39
IDO1 P14902 2/20 0.39
MAOB P27338 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 3/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4388294 0.86 MEN1 (0.51) MEN1KMT2ALMNANR4A2PRKCA
SCHEMBL4410979 0.85 MEN1 (0.48) MEN1KMT2ALMNANR4A2PRKCA
SCHEMBL4382696 0.83 KMT2A (0.53) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL4387904 0.83 MEN1 (0.47) MEN1KMT2ALMNANR4A2PRKCA
SCHEMBL4380358 0.81 LMNA (0.51) MEN1KMT2ALMNANR4A2SMN1; SMN2
SCHEMBL8212151 0.81 KMT2A (0.45) MEN1KMT2ALMNAMAOBMAPT
SCHEMBL8221599 0.81 KMT2A (0.45) MEN1KMT2ALMNAPRKCAPRKCD
SCHEMBL4395353 0.81 MEN1 (0.45) MEN1KMT2ALMNANR4A2PRKCA
SCHEMBL4382642 0.80 TACR1 (0.48) MEN1KMT2ALMNANR4A2PRKCA
Hydrochloric Acid SCHEMBL4383617 0.80 KMT2A (0.44) MEN1KMT2ALMNAMAOBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 EP disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 MEN1 3694/4885KMT2A 2079/4885TEAD1 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.